Published in Transplantation on April 15, 2009
Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice. Nat Med (2016) 2.15
How to make a functional β-cell. Development (2013) 1.58
Scalable stirred-suspension bioreactor culture of human pluripotent stem cells. Tissue Eng Part A (2010) 1.44
Immunological applications of stem cells in type 1 diabetes. Endocr Rev (2011) 1.20
Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist. Proc Natl Acad Sci U S A (2012) 1.14
Rat islet cell aggregates are superior to islets for transplantation in microcapsules. Diabetologia (2010) 1.14
Islets transplanted in immunoisolation devices: a review of the progress and the challenges that remain. Endocr Rev (2011) 1.10
Inconsistent formation and nonfunction of insulin-positive cells from pancreatic endoderm derived from human embryonic stem cells in athymic nude rats. Am J Physiol Endocrinol Metab (2010) 1.09
Stem cell approaches for diabetes: towards beta cell replacement. Genome Med (2011) 1.02
Islet transplantation and encapsulation: an update on recent developments. Rev Diabet Stud (2011) 0.98
Concise review: pancreas regeneration: recent advances and perspectives. Stem Cells Transl Med (2012) 0.98
Id3 upregulates BrdU incorporation associated with a DNA damage response, not replication, in human pancreatic β-cells. Islets (2011) 0.94
Real-time bioluminescence imaging of macroencapsulated fibroblasts reveals allograft protection in rhesus monkeys (Macaca mulatta). Transplantation (2009) 0.94
Concise review: workshop review: understanding and assessing the risks of stem cell-based therapies. Stem Cells Transl Med (2015) 0.92
Minireview: beta-cell replacement therapy for diabetes in the 21st century: manipulation of cell fate by directed differentiation. Mol Endocrinol (2010) 0.91
Stem cell-derived islet cells for transplantation. Curr Opin Organ Transplant (2011) 0.88
A shift from cell cultures to creatures: in vivo imaging of small animals in experimental regenerative medicine. Mol Ther (2011) 0.87
Tissue engineering 2.0: guiding self-organization during pluripotent stem cell differentiation. Curr Opin Biotechnol (2012) 0.85
Potential pathways to restore β-cell mass: pluripotent stem cells, reprogramming, and endogenous regeneration. Curr Diab Rep (2011) 0.82
Present and future cell therapies for pancreatic beta cell replenishment. World J Gastroenterol (2012) 0.81
Islet and stem cell encapsulation for clinical transplantation. Rev Diabet Stud (2014) 0.80
Re-engineering islet cell transplantation. Pharmacol Res (2015) 0.79
Human islet xenotransplantation in rodents: A literature review of experimental model trends. Clinics (Sao Paulo) (2017) 0.77
Recent developments in β-cell differentiation of pluripotent stem cells induced by small and large molecules. Int J Mol Sci (2014) 0.76
Cell therapies for pancreatic beta-cell replenishment. Ital J Pediatr (2016) 0.76
Therapeutic potential of human embryonic stem cells in type 2 diabetes mellitus. World J Stem Cells (2016) 0.75
Progress and challenges of the bioartificial pancreas. Nano Converg (2016) 0.75
Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol (2006) 10.95
Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol (2008) 10.60
Five-year follow-up after clinical islet transplantation. Diabetes (2005) 7.86
Recovery from diabetes in mice by beta cell regeneration. J Clin Invest (2007) 4.32
Genomic alterations in cultured human embryonic stem cells. Nat Genet (2005) 3.89
A second pathway for regeneration of adult exocrine and endocrine pancreas. A possible recapitulation of embryonic development. Diabetes (1993) 3.01
The murine autoimmune diabetes model: NOD and related strains. Adv Immunol (1992) 2.80
Magnetic resonance-guided, real-time targeted delivery and imaging of magnetocapsules immunoprotecting pancreatic islet cells. Nat Med (2007) 2.08
Effect of transplantation site on the results of pancreatic islet isografts in diabetic rats. Diabetologia (1973) 1.98
Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation. Transplantation (2005) 1.82
Neovascularization of synthetic membranes directed by membrane microarchitecture. J Biomed Mater Res (1995) 1.77
Implantable biohybrid artificial organs. Cell Transplant (1995) 1.65
Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. Proc Natl Acad Sci U S A (2006) 1.60
Proliferation and differentiation in the human fetal endocrine pancreas. Diabetologia (1997) 1.39
Six-month survival of microencapsulated pig islets and alginate biocompatibility in primates: proof of concept. Transplantation (2006) 1.35
Factors influencing the loss of beta-cell mass in islet transplantation. Cell Transplant (2007) 1.27
Bioluminescent monitoring of islet graft survival after transplantation. Mol Ther (2004) 1.21
Alginate polycation microcapsules. II. Some functional properties. Biomaterials (1996) 1.11
Autoimmunity to both proinsulin and IGRP is required for diabetes in nonobese diabetic 8.3 TCR transgenic mice. J Immunol (2008) 1.11
Long-term graft function of adult rat and human islets encapsulated in novel alginate-based microcapsules after transplantation in immunocompetent diabetic mice. Diabetes (2005) 1.10
Islet encapsulation: strategies to enhance islet cell functions. Tissue Eng (2007) 1.09
Transplantation of micro- and macroencapsulated piglet islets into mice and monkeys. Transplant Proc (2005) 1.07
Presented antigen from damaged pancreatic beta cells activates autoreactive T cells in virus-mediated autoimmune diabetes. J Clin Invest (2002) 1.07
Potential of embryonic and adult stem cells in vitro. Biol Chem (2003) 1.06
Experimental transplantation of human fetal and adult pancreatic islets. J Clin Endocrinol Metab (1997) 1.05
Species differences in susceptibility of transplanted and cultured pancreatic islets to the beta-cell toxin alloxan. Gen Comp Endocrinol (2001) 1.01
Functional beta-cell mass after transplantation of human fetal pancreatic cells: differentiation or proliferation? Diabetes (1997) 1.00
Caspase inhibitor therapy enhances marginal mass islet graft survival and preserves long-term function in islet transplantation. Diabetes (2007) 0.97
Local inflammatory response around diffusion chambers containing xenografts. Nonspecific destruction of tissues and decreased local vascularization. Transplantation (1996) 0.93
Function and survival of macroencapsulated syngeneic islets transplanted into streptozocin-diabetic mice. Transplantation (1998) 0.93
Isolation and characterization of a cell line from the epithelial cells of the human fetal pancreas. Cell Transplant (1997) 0.92
Histologic differentiation of human fetal pancreatic explants transplanted into nude mice. Diabetes (1984) 0.91
Xenotransplantation of neonatal porcine liver cells. Transplant Proc (2005) 0.88
Survival of macroencapsulated allogeneic parathyroid tissue one year after transplantation in nonimmunosuppressed humans. Cell Transplant (2001) 0.88
Number and volume of islets transplanted in immunobarrier devices. Cell Transplant (1998) 0.87
Acid beta-galactosidase: a developmentally regulated marker of endocrine cell precursors in the human fetal pancreas. J Clin Endocrinol Metab (1994) 0.86
Inhibition of membrane type-1 matrix metalloproteinase by cancer drugs interferes with the homing of diabetogenic T cells into the pancreas. J Biol Chem (2005) 0.86
A new strategy toward improving immunoprotection in cell therapy for diabetes mellitus: long-functioning PEGylated islets in vivo. Tissue Eng (2006) 0.86
Correction of diabetic nod mice with insulinomas implanted within Baxter immunoisolation devices. J Mol Med (Berl) (1999) 0.86
Improved survival of macroencapsulated islets of Langerhans by preimplantation of the immunoisolating device: a morphometric study. Cell Transplant (2003) 0.85
Survival of pancreatic islet xenografts in NOD mice with the theracyte device. Transplant Proc (2002) 0.83
Effects of micro-encapsulation on morphology and endocrine function of cryopreserved neonatal porcine islet-like cell clusters. Transplantation (2000) 0.80
Cell-based therapies for diabetes: progress towards a transplantable human beta cell line. Ann N Y Acad Sci (2003) 0.80
Treatment of osteoporosis with TheraCyte-encapsulated parathyroid cells: a study in a rat model. Osteoporos Int (2006) 0.80
Protection of xenografts by a combination of immunoisolation and a single dose of anti-CD4 antibody. Cell Transplant (2001) 0.79
Use of an immunoisolation device for cell transplantation and tumor immunotherapy. Ann N Y Acad Sci (1997) 0.78
Subcutaneous transplantation of rat islets into diabetic nude. Transplant Proc (1998) 0.76
Immunoisolation of tumor cells: generation of antitumor immunity through indirect presentation of antigen. J Immunother (1997) 0.76
Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol (2003) 7.89
Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell (2008) 4.63
A chemical platform for improved induction of human iPSCs. Nat Methods (2009) 4.54
Long-term self-renewal and directed differentiation of human embryonic stem cells in chemically defined conditions. Proc Natl Acad Sci U S A (2006) 3.90
Sox9+ ductal cells are multipotent progenitors throughout development but do not produce new endocrine cells in the normal or injured adult pancreas. Development (2011) 3.11
Revealing a core signaling regulatory mechanism for pluripotent stem cell survival and self-renewal by small molecules. Proc Natl Acad Sci U S A (2010) 3.01
A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci (2005) 2.54
Beta-cell differentiation from nonendocrine epithelial cells of the adult human pancreas. Nat Med (2006) 2.41
Generation of human-induced pluripotent stem cells in the absence of exogenous Sox2. Stem Cells (2009) 2.29
Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci U S A (2009) 2.02
Pancreatic β-cell neogenesis by direct conversion from mature α-cells. Stem Cells (2010) 1.80
Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold. Protein Sci (2007) 1.63
A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell (2013) 1.59
Simultaneous visualization of protumorigenic Src and MT1-MMP activities with fluorescence resonance energy transfer. Cancer Res (2010) 1.50
Cleavage targets and the D-arginine-based inhibitors of the West Nile virus NS3 processing proteinase. Biochem J (2006) 1.49
A novel approach to increase human islet cell mass while preserving beta-cell function. Diabetes (2002) 1.43
The basic helix-loop-helix transcription factor E47 reprograms human pancreatic cancer cells to a quiescent acinar state with reduced tumorigenic potential. Pancreas (2015) 1.42
HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus. Assay Drug Dev Technol (2007) 1.40
Substrate cleavage analysis of furin and related proprotein convertases. A comparative study. J Biol Chem (2008) 1.40
Tissue inhibitor of metalloproteinases-2 binding to membrane-type 1 matrix metalloproteinase induces MAPK activation and cell growth by a non-proteolytic mechanism. J Biol Chem (2007) 1.40
Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase. J Biol Chem (2001) 1.35
A unique substrate binding mode discriminates membrane type-1 matrix metalloproteinase from other matrix metalloproteinases. J Biol Chem (2002) 1.33
Efficient synthetic inhibitors of anthrax lethal factor. Proc Natl Acad Sci U S A (2005) 1.32
Membrane type-1 matrix metalloproteinase (MT1-MMP) exhibits an important intracellular cleavage function and causes chromosome instability. J Biol Chem (2005) 1.30
Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis. Cancer Res (2002) 1.27
Anthrax lethal factor protease inhibitors: synthesis, SAR, and structure-based 3D QSAR studies. J Med Chem (2006) 1.27
Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells. J Biol Chem (2009) 1.24
An alternative processing of integrin alpha(v) subunit in tumor cells by membrane type-1 matrix metalloproteinase. J Biol Chem (2001) 1.24
The low density lipoprotein receptor-related protein LRP is regulated by membrane type-1 matrix metalloproteinase (MT1-MMP) proteolysis in malignant cells. J Biol Chem (2003) 1.20
Progenitor cell domains in the developing and adult pancreas. Cell Cycle (2011) 1.20
The MMP-9/TIMP-1 axis controls the status of differentiation and function of myelin-forming Schwann cells in nerve regeneration. PLoS One (2012) 1.18
The Wnt/planar cell polarity protein-tyrosine kinase-7 (PTK7) is a highly efficient proteolytic target of membrane type-1 matrix metalloproteinase: implications in cancer and embryogenesis. J Biol Chem (2010) 1.17
Molecular signature of MT1-MMP: transactivation of the downstream universal gene network in cancer. Cancer Res (2008) 1.14
Membrane type-1 matrix metalloproteinase (MT1-MMP) processing of pro-alphav integrin regulates cross-talk between alphavbeta3 and alpha2beta1 integrins in breast carcinoma cells. Exp Cell Res (2003) 1.13
Matrix metalloproteinase proteolysis of the myelin basic protein isoforms is a source of immunogenic peptides in autoimmune multiple sclerosis. PLoS One (2009) 1.11
The transmembrane domain is essential for the microtubular trafficking of membrane type-1 matrix metalloproteinase (MT1-MMP). J Cell Sci (2005) 1.10
Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins. Br J Pharmacol (2003) 1.08
Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem (2007) 1.08
Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth. Cancer Res (2012) 1.08
Promoter characterization of the novel human matrix metalloproteinase-26 gene: regulation by the T-cell factor-4 implies specific expression of the gene in cancer cells of epithelial origin. Biochem J (2002) 1.08
Interaction of hepatitis B viral oncoprotein with cellular target HBXIP dysregulates centrosome dynamics and mitotic spindle formation. J Biol Chem (2007) 1.08
Cleavage preference distinguishes the two-component NS2B-NS3 serine proteinases of Dengue and West Nile viruses. Biochem J (2007) 1.07
beta-cell Regeneration: neogenesis, replication or both? J Mol Med (Berl) (2007) 1.06
Timp-2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells. Int J Cancer (2010) 1.04
Aberrant, persistent inclusion into lipid rafts limits the tumorigenic function of membrane type-1 matrix metalloproteinase in malignant cells. Exp Cell Res (2004) 1.04
The two-component NS2B-NS3 proteinase represses DNA unwinding activity of the West Nile virus NS3 helicase. J Biol Chem (2008) 1.04
Gelatin zymography and substrate cleavage assays of matrix metalloproteinase-2 in breast carcinoma cells overexpressing membrane type-1 matrix metalloproteinase. Lab Invest (2002) 1.03
Membrane type-1 matrix metalloproteinase confers aneuploidy and tumorigenicity on mammary epithelial cells. Cancer Res (2006) 1.03
The cytoplasmic tail peptide sequence of membrane type-1 matrix metalloproteinase (MT1-MMP) directly binds to gC1qR, a compartment-specific chaperone-like regulatory protein. FEBS Lett (2002) 1.02
Microarray-based transcriptional and epigenetic profiling of matrix metalloproteinases, collagens, and related genes in cancer. J Biol Chem (2010) 1.02
Switching the substrate specificity of the two-component NS2B-NS3 flavivirus proteinase by structure-based mutagenesis. J Virol (2007) 1.02
Beta-catenin regulates the gene of MMP-26, a novel metalloproteinase expressed both in carcinomas and normal epithelial cells. Int J Biochem Cell Biol (2004) 1.02
Proteolysis of the membrane type-1 matrix metalloproteinase prodomain: implications for a two-step proteolytic processing and activation. J Biol Chem (2007) 1.01
Limited capacity of human adult islets expanded in vitro to redifferentiate into insulin-producing beta-cells. Diabetes (2007) 1.01
Coordinated regulation by Shp2 tyrosine phosphatase of signaling events controlling insulin biosynthesis in pancreatic beta-cells. Proc Natl Acad Sci U S A (2009) 0.98
O-glycosylation regulates autolysis of cellular membrane type-1 matrix metalloproteinase (MT1-MMP). J Biol Chem (2006) 0.97
Autocatalytic activation of the furin zymogen requires removal of the emerging enzyme's N-terminus from the active site. PLoS One (2009) 0.97
Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients. Cancer Res (2006) 0.97
Matrix metalloproteinase-26 is associated with estrogen-dependent malignancies and targets alpha1-antitrypsin serpin. Cancer Res (2004) 0.96
Mixed lineage kinase-3 stabilizes and functionally cooperates with TRIBBLES-3 to compromise mitochondrial integrity in cytokine-induced death of pancreatic beta cells. J Biol Chem (2010) 0.96
Inflammatory proprotein convertase-matrix metalloproteinase proteolytic pathway in antigen-presenting cells as a step to autoimmune multiple sclerosis. J Biol Chem (2009) 0.95
Expression and purification of a two-component flaviviral proteinase resistant to autocleavage at the NS2B-NS3 junction region. Protein Expr Purif (2006) 0.95
Membrane-type-1 matrix metalloproteinase confers tumorigenicity on nonmalignant epithelial cells. Oncogene (2005) 0.94
Cell-surface-associated tissue transglutaminase is a target of MMP-2 proteolysis. Biochemistry (2004) 0.94
Id3 upregulates BrdU incorporation associated with a DNA damage response, not replication, in human pancreatic β-cells. Islets (2011) 0.94
Real-time bioluminescence imaging of macroencapsulated fibroblasts reveals allograft protection in rhesus monkeys (Macaca mulatta). Transplantation (2009) 0.94
Immunodominant fragments of myelin basic protein initiate T cell-dependent pain. J Neuroinflammation (2012) 0.94
Membrane type-1 matrix metalloproteinase (MT1-MMP) protects malignant cells from tumoricidal activity of re-engineered anthrax lethal toxin. Int J Biochem Cell Biol (2005) 0.93
Islet specific Wnt activation in human type II diabetes. Exp Diabetes Res (2009) 0.93
Delayed administration of a matrix metalloproteinase inhibitor limits progressive brain injury after hypoxia-ischemia in the neonatal rat. J Neuroinflammation (2008) 0.92
Potential relation of aberrant proteolysis of human protein tyrosine kinase 7 (PTK7) chuzhoi by membrane type 1 matrix metalloproteinase (MT1-MMP) to congenital defects. J Biol Chem (2011) 0.92
NS4A regulates the ATPase activity of the NS3 helicase: a novel cofactor role of the non-structural protein NS4A from West Nile virus. J Gen Virol (2009) 0.92
c-Myc controls proliferation versus differentiation in human pancreatic endocrine cells. J Clin Endocrinol Metab (2002) 0.92
Centrosomal pericentrin is a direct cleavage target of membrane type-1 matrix metalloproteinase in humans but not in mice: potential implications for tumorigenesis. J Biol Chem (2005) 0.90
New details of HCV NS3/4A proteinase functionality revealed by a high-throughput cleavage assay. PLoS One (2012) 0.90
Non-proteolytic, receptor/ligand interactions associate cellular membrane type-1 matrix metalloproteinase with the complement component C1q. J Biol Chem (2004) 0.89
High-resolution analysis and functional mapping of cleavage sites and substrate proteins of furin in the human proteome. PLoS One (2013) 0.89
Prointegrin maturation follows rapid trafficking and processing of MT1-MMP in Furin-Negative Colon Carcinoma LoVo Cells. Traffic (2004) 0.89
CENP-A, a protein required for chromosome segregation in mitosis, declines with age in islet but not exocrine cells. Aging (Albany NY) (2010) 0.89
The hemopexin-like C-terminal domain of membrane type 1 matrix metalloproteinase regulates proteolysis of a multifunctional protein, gC1qR. J Biol Chem (2001) 0.88
Crystal and solution structures of a prokaryotic M16B peptidase: an open and shut case. Structure (2009) 0.88
Biochemical characterization of the cellular glycosylphosphatidylinositol-linked membrane type-6 matrix metalloproteinase. J Biol Chem (2010) 0.88
Substrate cleavage profiling suggests a distinct function of Bacteroides fragilis metalloproteinases (fragilysin and metalloproteinase II) at the microbiome-inflammation-cancer interface. J Biol Chem (2013) 0.88
Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells. Mol Cancer Ther (2009) 0.88
Insights into ectodomain shedding and processing of protein-tyrosine pseudokinase 7 (PTK7). J Biol Chem (2012) 0.88
HNF4α antagonists discovered by a high-throughput screen for modulators of the human insulin promoter. Chem Biol (2012) 0.88
Phenothiazine neuroleptics signal to the human insulin promoter as revealed by a novel high-throughput screen. J Biomol Screen (2010) 0.88